Latest Healthcare News

MedAdvisor Limited reports a steep decline in 3Q FY25 revenue, driven by US market challenges, while accelerating cost-cutting and reaffirming full-year guidance.

Constellation Technologies Limited reports sustained sales growth and positive cash flow in Q3 2025, driven by its Callisto Food Safety & Compliance system and strategic market expansion.

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Appen Limited reported a 12% revenue increase excluding Google in Q1 FY25, alongside a significant improvement in underlying EBITDA and a robust cash position, setting a positive tone for the year ahead.

Biome Australia is set to expand its Activated Probiotics range with two new products targeting vaginal health and perinatal care, tapping into a booming women’s health supplements market.

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

Visionflex Group reported a 46% year-on-year rise in annual recurring revenue to $1.7 million, secured key contracts including a $1 million virtual nursing pilot, and targets operating cash flow positivity in Q4 FY25.

CurveBeam AI reported a robust 40% increase in purchase orders during Q3 FY25 and secured a non-binding A$18 million vendor financing term sheet, positioning the company for cashflow positivity in Q4.

Control Bionics reports its strongest US revenue in years alongside Australia’s best quarter since 2022, propelled by new product launches and strategic investments.